Cargando…
Studies on the Efficacy, Potential Cardiotoxicity and Monkey Pharmacokinetics of GLP-26 as a Potent Hepatitis B Virus Capsid Assembly Modulator
While treatment options are available for hepatitis B virus (HBV), there is currently no cure. Anti-HBV nucleoside analogs and interferon-alpha 2b rarely clear HBV covalently closed circular DNA (cccDNA), requiring lifelong treatment. Recently, we identified GLP-26, a glyoxamide derivative which mod...
Autores principales: | Hurwitz, Selwyn J., McBrearty, Noreen, Arzumanyan, Alla, Bichenkov, Eugene, Tao, Sijia, Bassit, Leda, Chen, Zhe, Kohler, James J., Amblard, Franck, Feitelson, Mark A., Schinazi, Raymond F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830897/ https://www.ncbi.nlm.nih.gov/pubmed/33467678 http://dx.doi.org/10.3390/v13010114 |
Ejemplares similares
-
Short chain fatty acids delay the development of hepatocellular carcinoma in HBx transgenic mice
por: McBrearty, Noreen, et al.
Publicado: (2021) -
Approaches to hepatitis C treatment and cure using NS5A inhibitors
por: Kohler, James J, et al.
Publicado: (2014) -
Assessment of a Computational Approach to Predict Drug Resistance Mutations for HIV, HBV and SARS-CoV-2
por: Patel, Dharmeshkumar, et al.
Publicado: (2022) -
A Spiroligomer α-Helix Mimic That Binds HDM2, Penetrates Human Cells and Stabilizes HDM2 in Cell Culture
por: Brown, Zachary Z., et al.
Publicado: (2012) -
Electronics Calculations Data Handbook
por: McBrearty, Daniel
Publicado: (1998)